
RLIP76 GENE VARIANTS ARE NOT ASSOCIATED WITH
DRUG RESPONSE IN TURKISH EPILEPSY PATIENTS Manguoğlu E1,*, Akdeniz S1, Dündar NO2, Duman Ö2,
Aktekin B3, Haspolat Ş2, Bilge U4, Özel D4, Lüleci G1 *Corresponding Author: Esra Manguoğlu, Department of Medical Biology and Genetics, Faculty of Medicine,
Akdeniz University, Antalya, Turkey;
Tel.: +90-242-249-6977; Fax: +90-242-249-6906; E-mail: emanguoglu@akdeniz.edu.tr page: 25
|
MATERIALS AND METHOD
Patients. A total of 146 (81 male and 65 female)
refractory and 155 (79 male and 76 female) non refractory
patients were recruited for the study. The mean
age for refractory and non refractory groups were 34.4
± 17.8 (ranging from 3 to 83 years) and 25.4 ± 17.5
(ranging from 2 to 78 years), respectively. One-hundred
and forty-three the patients were above the age of
18, while 158 patients were below the age of 18. Patients who were seizure free for at least 1 year
were regarded as non refractory epilepsy patients. Patients,
who had seizures, in spite of taking at least three
different AEDs with maximum tolerable doses, were
considered to be refractory epilepsy patients.
This study was approved by the Akdeniz University
Ethics Committee (Antalya, Turkey). Information
about the study was given to all patients. A signed, informed
consent was obtained from all patients or from
adults responsible for them. Patients were recruited
from Akdeniz University Hospital, Departments of Pediatrics
and Neurology (Antalya, Turkey). All patients
were Turkish.
Genotyping. DNA isolation from peripheral leukocytes
was performed by a standard salting-out method
[13]. All coding exons (exons 2-10) and exon-intron
boundaries of the RLIP76 (RALBP1, NM_006788.3)
gene were screened for sequence changes by denaturing
high performance liquid chromatography (HPLC). The
polymerase chain reaction (PCR) primer sequences are
given in Table 1. The PCR reactions were set up in 20 ML
volume with 10-20 ng DNA, 0.5 U Optimase Taq DNA
polymerase, using a PE9700 thermal cycler [Applied
Biosystems Inc. (ABI), Foster City, CA, USA]. Amplifications
were done by touch-down PCR with annealing
temperature with decreasing increments of 0.5°C
in each cycle starting from 61°C to 54°C. Denaturing
HPLC analyses were performed on a Transgenomic
(Omaha, NE, USA) Wave HS nucleic acid fragment
analysis system with DNASep cartridges, WAVE Optimized
buffers and standards. To increase the sensitivity
of these analyses, they were performed on at least two
different oven temperatures for each PCR fragment.
All regions that have denaturing HPLC patterns suggesting
a sequence change were sequenced successfully
to define the sequence change. The PCR products
were purified using a Roche High Pure PCR product
purification kit (catalog no. 11 732 676 001; Roche
Applied Science, Indianapolis, IN, USA). A direct sequencing
protocol was applied and BigDye Terminator
v.1.1 cycle sequencing system was used (Applied Biosystems).
Sequencing samples were separated using an
ABI 3130™ system (Applied Biosystems).
Statistical Analysis. When minimum expected
values were less than 5, the Fisher’s Exact test was
used. When the minimum expected value was between
5 and 25, the Yate’s Continuity Correction test
was used. In all other circumstances, the Pearson χ2
(Chi-square) test was used. Statistical analysis was
performed with SPSS version 15 (SPSS Inc., Chicago, IL, USA); p <0.05 was considered to be statistically
significant.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|